Peringkat dalam Saham
#37553
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical... Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Harga Saham
$0.07
Terakhir disinkronkan: 2024-11-12
Kapitalisasi Pasar
$1.62M
Perubahan (1 tahun)
0.00%
Perdagangan Peak Bio, Inc. (PKBO)
Harga PKBO dengan kapitalisasi pasar B
Kapitalisasi pasar dari Peak Bio, Inc.(PKBO)
Kapitalisasi Pasar: $1.62M
Per August 2026, Peak Bio, Inc. memiliki kapitalisasi pasar sebesar $1.62M. Ini menjadikan Peak Bio, Inc. sebagai perusahaan 37553rd paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Peak Bio, Inc. dari 2021 hingga 2026
PKBO dibandingkan dengan 5 teratas stocks paling populer
| Harga PKBO |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.452T
|
+336,854,984.03%
|
|
|
|
|
$4.490T
|
+277,425,214.66%
|
|
|
|
|
$4.162T
|
+257,182,948.93%
|
|
|
|
|
$3.676T
|
+227,150,429.30%
|
|
|
|
|
$2.833T
|
+175,045,381.37%
|
